# Cyanobacteria-Derived Extracellular Vesicles: A Novel Frontier in Drug Delivery and Therapeutics

**Authors:** Khalid A. Asseri, Krishnaraju Venkatesan, Yahya I. Asiri, Saud Alqahtani, Taha Alqahtani, Pooja Muralidharan, Shaimaa Elsayed Ramadan Genena, Durgaramani Sivadasan, Premalatha Paulsamy, Kumarappan Chidambaram

PMC · DOI: 10.3390/ijms27010004 · International Journal of Molecular Sciences · 2025-12-19

## TL;DR

Cyanobacteria produce extracellular vesicles that show promise as natural drug delivery systems for treating diseases like cancer and infections.

## Contribution

This review systematically explores the potential of cyanobacterial extracellular vesicles as novel nanocarriers for drug delivery.

## Key findings

- Cyanobacterial EVs are biocompatible and stable, making them suitable for encapsulating bioactive compounds.
- They offer advantages over synthetic nanocarriers in targeted drug delivery and immune modulation.
- Challenges remain in large-scale isolation and characterization of these vesicles.

## Abstract

Cyanobacteria, known for their diverse and potent bioactive compounds, present a unique method for drug delivery via their extracellular vesicles (EVs), often described as exosome-like due to size and function but distinct in biogenesis. These naturally occurring vesicles, particularly those from cyanobacteria, are gaining attention as potential carriers for targeted drug delivery because of their biocompatibility, stability, and ability to encapsulate various bioactive compounds. However, cyanobacterial EVs remain underexplored as a dedicated nanocarrier platform, and their specific advantages and limitations relative to existing systems have not been systematically synthesized. This review explores the potential therapeutic uses of cyanobacterial EVs, emphasizing their roles in cancer treatment, antimicrobial therapies, neuroprotection, and immune modulation. We explore their biogenesis and structural features, comparing them to synthetic nanocarriers like polymeric nanoparticles and liposomes. The review also addresses the challenges of isolating and characterizing cyanobacterial EVs at scale and highlights the need for advancements in synthetic biology and genetic engineering to optimize their therapeutic potential. Despite these challenges, cyanobacterial EVs’ unique properties offer significant promise for advancing drug delivery systems and providing innovative solutions for treating complex diseases.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12785971/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12785971/full.md

## References

134 references — full list in the complete paper: https://tomesphere.com/paper/PMC12785971/full.md

---
Source: https://tomesphere.com/paper/PMC12785971